Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Apr 27, 2012

EC Sanctions Pharmaxis’ Bronchitol as Add-On Therapy for Cystic Fibrosis

  • Respiratory disease therapeutics firm Pharmaxis achieved EC approval for its cystic fibrosis therapy Bronchitol. It is indicated for use in helping to clear the airways of mucus as an add-on therapy to best standard of care.  Clearance across the 29 European countries was based on data from two Phase III studies, which showed that the dry powder inhaled mannitol formulation improved mucus clearance, improved lung function, and reduced infectious episodes.

    Bronchitol was first granted marketing clearance in Australia in February 2011. The product is also undergoing Phase III development in patients with bronchiectasis. One study has been completed, and a second global Phase III study is evaluating the efficacy of Bronchitol for reducing infectious episodes, antibiotic use, and hospitalization time.

    Australian firm Pharmaxis’ first marketed product, Aridol®/Osmohale, is an indirect osmotic bronchial challenge test kit used to aid in the diagnosis of asthma by assessing  bronchial hyperresponsiveness in children and adults. The product is approved in Australia, major European countries, South Korea, and the U.S. Pharmaxis says the test is the only Europe-wide approved lung function test, and the world's first approved indirect challenge test for asthma.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »